Investor Presentaiton
Highly Diversified Revenue Base
Sun Pharma (Pre Ranbaxy Acquisition)
Rest of
World##
12%
API & Others
5%
5 year CAGR: 11%
India Branded
Formulations
23%
5 year CAGR: 38%
US
Formulations
60%
5 year CAGR: 45%
FY14 Sales**
Rs 162 billion
SUN
PHARMA
Sun Pharma (Post Ranbaxy Acquisition)
Emerging
Markets
14%
5 year CAGR: 14%
India Branded
Formulations
24%
Western
FY15 Sales*
Europe &
Other
Markets #
8%
API & Others
4%
Rs 276 billion
US
Formulations
50%
**
Sales for Sun Pharma (excluding Ranbaxy) for 12 months ended Mar' 14.
## Includes all formulations sales excluding US and India
*
Sales for Sun Pharma (including Ranbaxy) for 12 months ended Mar' 15.
# Includes Western Europe, Canada, Australia & New Zealand, Japan and other markets.
© Sun Pharmaceutical Industries Limited. All Rights Reserved.
9View entire presentation